type	clinical_trial_id	title	last_update_posted	recruitment_status	project.project_id
clinical_trial	NCT01713582	A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)	26-Jan-21	Completed	3R01CA124633-11A1S1
clinical_trial	NCT01713582	A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)	26-Jan-21	Completed	5R01CA176745-09
clinical_trial	NCT02259114	"A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)"	26-Jan-21	Completed	3R01CA124633-11A1S1
clinical_trial	NCT02259114	"A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)"	26-Jan-21	Completed	5R01CA176745-09
clinical_trial	NCT02296476	A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)	26-Jan-21	Terminated	3R01CA124633-11A1S1
clinical_trial	NCT02296476	A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)	26-Jan-21	Terminated	5R01CA176745-09
clinical_trial	NCT01587703	"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers"	16-Mar-20	Completed	3R01CA124633-11A1S1
clinical_trial	NCT01987362	A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies	5-Jan-18	Completed	3R01CA124633-11A1S1
clinical_trial	NCT01987362	A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies	5-Jan-18	Completed	5R01CA176745-09
clinical_trial	NCT02158858	A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis	29-Jan-21	Recruiting	3R01CA124633-11A1S1
clinical_trial	NCT02431260	"An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies"	14-Jun-19	Terminated	3R01CA124633-11A1S1
clinical_trial	NCT02307240	"Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors"	3-Sep-19	Completed	3R01CA124633-11A1S1
clinical_trial	NCT02427451	"Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia"	6-Nov-19	"Active, not recruiting"	3R01CA205967-03S2
clinical_trial	NCT03098160	Immunotherapy Study of Evofosfamide in Combination With Ipilimumab	30-Oct-17	Unknown	3R01CA187532-03S1
clinical_trial	NCT02744287	Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors	26-Apr-21	Recruiting	3R01CA163915-07S1
clinical_trial	NCT02744287	Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors	26-Apr-21	Recruiting	1U54CA244438-01
clinical_trial	NCT02744287	Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors	26-Apr-21	Recruiting	3P30CA013696-45S1
clinical_trial	NCT02743611	Safety &amp; Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma	27-Apr-20	"Active, not recruiting"	3R01CA163915-07S1
clinical_trial	NCT01896479	"A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER)"	26-Jul-21	"Active, not recruiting"	5UM1CA228823-03
clinical_trial	NCT01709435	Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors	7-Apr-20	Completed	5UM1CA228823-03
clinical_trial	NCT02867592	"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors"	16-Aug-21	"Active, not recruiting"	5UM1CA228823-03
clinical_trial	NCT01780662	Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma	16-Jun-21	"Active, not recruiting"	5UM1CA228823-03
clinical_trial	NCT00106015	Diamond Blackfan Anemia Registry (DBAR) (DBAR)	4-Mar-21	Recruiting	1R01CA211723-01A1
clinical_trial	NCT02164838	VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors	29-Jan-18	Completed	5UM1CA228823-03
clinical_trial	NCT01657682	A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations	20-Jul-20	Completed	3R01CA182543-05S2
clinical_trial	NCT02639026	"Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers"	9-Mar-21	"Active, not recruiting"	1U01CA224175-01
clinical_trial	NCT02648282	"Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer"	9-Aug-21	"Active, not recruiting"	1U01CA224175-01
clinical_trial	NCT03245541	Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer	9-Aug-21	Recruiting	1U01CA224175-01
clinical_trial	NCT03190265	"Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer"	11-May-21	Recruiting	1U01CA224175-01
clinical_trial	NCT02451982	Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer	22-Mar-21	Recruiting	1U01CA224175-01
clinical_trial	NCT03153410	"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas"	19-Aug-21	"Active, not recruiting"	1U01CA224175-01
clinical_trial	NCT03006302	"Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer"	18-Mar-21	Recruiting	1U01CA224175-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	30-Jul-21	"Active, not recruiting"	1U01CA224175-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	30-Jul-21	"Active, not recruiting"	1U01CA224193-01
clinical_trial	NCT02758587	Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)	19-Mar-18	Recruiting	1U01CA224175-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	20-Jul-21	Completed	1U01CA224175-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	20-Jul-21	Completed	1U54CA224083-01
clinical_trial	NCT03481920	A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer	22-Aug-19	Terminated	1U01CA224175-01
clinical_trial	NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	5-Aug-21	"Active, not recruiting"	1U01CA224175-01
clinical_trial	NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	5-Aug-21	"Active, not recruiting"	1U01CA224193-01
clinical_trial	NCT03634332	Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC	7-May-19	Unknown	1U01CA224175-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	5-Feb-20	Completed	1U01CA224175-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	31-Jul-20	Completed	1U01CA224175-01
clinical_trial	NCT02436668	"Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)"	30-Dec-20	Completed	1U01CA224175-01
clinical_trial	NCT03496662	BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)	23-Jul-21	Recruiting	1U01CA224175-01
clinical_trial	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)	10-Jun-21	Recruiting	1U01CA224175-01
clinical_trial	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)	10-Jun-21	Recruiting	1U01CA224193-01
clinical_trial	NCT00798213	SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)	4-Feb-15	Terminated	1U24CA224067-01
clinical_trial	NCT00937937	Dinaciclib in Treating Patients With Stage IV Melanoma	5-Aug-21	"Active, not recruiting"	1U24CA224067-01
clinical_trial	NCT03253679	AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification	16-Aug-21	Suspended	1U24CA224067-01
clinical_trial	NCT03478397	Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project) (ATICA)	6-Apr-21	Completed	1R01CA218306-01
clinical_trial	NCT01130077	A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas	10-Aug-21	"Active, not recruiting"	2UM1CA081457-21
clinical_trial	NCT02358031	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)	23-Oct-20	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02358031	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)	23-Oct-20	"Active, not recruiting"	1U01DE029255-01
clinical_trial	NCT02741570	Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651)	19-Apr-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT00771641	Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck	24-Jan-14	Completed	1R33CA225291-01
clinical_trial	NCT03383094	Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer	8-Feb-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03317327	REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT)	30-Sep-19	Recruiting	1R33CA225291-01
clinical_trial	NCT03546582	SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)	3-Aug-21	Recruiting	1R33CA225291-01
clinical_trial	NCT02296684	Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma	8-Dec-20	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02296684	Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma	8-Dec-20	"Active, not recruiting"	3U24CA237719-02S1
clinical_trial	NCT03051906	"Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (DUCRO-HN)"	22-Nov-17	Not yet recruiting	1R33CA225291-01
clinical_trial	NCT02999087	Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (REACH)	4-Nov-20	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02764593	Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer	3-Aug-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03247712	Neoadjuvant Immunoradiotherapy in Head &amp; Neck Cancer	20-May-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03673735	Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC (ADHERE)	10-May-21	Withdrawn	1R33CA225291-01
clinical_trial	NCT03529422	Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN	11-May-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03426657	Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC	11-Jun-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03509012	Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)	21-Jul-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03539198	Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer	5-Apr-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03085719	Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN	13-Nov-20	Recruiting	1R33CA225291-01
clinical_trial	NCT03283605	Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas	27-May-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03313804	Priming Immunotherapy in Advanced Disease With Radiation	14-Jun-21	Recruiting	1R33CA225291-01
clinical_trial	NCT02777385	Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer	6-Apr-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03349710	"Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer"	9-Aug-21	Completed	1R33CA225291-01
clinical_trial	NCT02892201	Pembrolizumab in HNSCC With Residual Disease After Radiation	15-Jul-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02841748	"A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study"	7-Jan-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03040999	Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)	19-Apr-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02952586	Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)	22-Jun-21	Terminated	1R33CA225291-01
clinical_trial	NCT02952586	Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)	22-Jun-21	Terminated	1U01DE029188-01
clinical_trial	NCT03452137	A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck	5-Aug-21	Recruiting	1R33CA225291-01
clinical_trial	NCT01302834	Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer	23-Feb-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT01040832	EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Na&#239;ve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	30-Jan-17	Completed	1R33CA225291-01
clinical_trial	NCT01334177	"TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck"	5-Mar-15	Completed	1R33CA225291-01
clinical_trial	NCT01360827	EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck	17-Jun-14	Terminated	1R33CA225291-01
clinical_trial	NCT01468896	"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery"	22-Mar-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT01836029	Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	29-Oct-19	Completed	1R33CA225291-01
clinical_trial	NCT01935921	"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer"	15-Jun-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02110082	Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer	19-Apr-17	Completed	1R33CA225291-01
clinical_trial	NCT02124850	A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab	25-Oct-19	Terminated	1R33CA225291-01
clinical_trial	NCT02633800	Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )	7-Jan-19	Terminated	1R33CA225291-01
clinical_trial	NCT02643550	Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	9-Feb-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02938273	Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)	11-Dec-19	Completed	1R33CA225291-01
clinical_trial	NCT03082534	Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	11-Mar-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03370276	Cetuximab &amp; Nivolumab in Patients With Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	12-Apr-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03494322	EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (EACH)	5-Nov-20	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03498378	"Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma"	19-Oct-20	Recruiting	1R33CA225291-01
clinical_trial	NCT01860430	"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer"	15-Jun-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02581137	Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion	5-Aug-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03074513	Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	24-Feb-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT01195922	Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma	6-Dec-17	Completed	1R33CA225291-01
clinical_trial	NCT01023386	A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer	13-Apr-10	Completed	1U54CA231652-01
clinical_trial	NCT00818480	An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155	4-Sep-15	Completed	1U54CA231652-01
clinical_trial	NCT01007292	A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment	19-Oct-15	Completed	1U54CA231652-01
clinical_trial	NCT01009775	A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma	4-Sep-15	Completed	1U54CA231652-01
clinical_trial	NCT01038804	A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer	18-Sep-13	Completed	1U54CA231652-01
clinical_trial	NCT00498914	Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects	4-Sep-15	Terminated	1U54CA231652-01
clinical_trial	NCT01100931	"A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)"	19-Oct-15	Completed	1U54CA231652-01
clinical_trial	NCT00514267	An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors	13-Aug-15	Completed	1U54CA231652-01
clinical_trial	NCT00281541	A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma	7-Jun-12	Completed	1U54CA231652-01
clinical_trial	NCT00328588	LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy	2-Jan-08	Completed	1U54CA231652-01
clinical_trial	NCT00257478	A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy	7-Jun-12	Completed	1U54CA231652-01
clinical_trial	NCT02579226	"A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors."	1-May-20	Completed	3R01CA204915-02S1
clinical_trial	NCT01089101	Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma	5-Apr-21	"Active, not recruiting"	2UM1CA081457-21
clinical_trial	NCT02595866	"Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms"	5-Aug-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT02639546	Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)	2-Jul-21	"Active, not recruiting"	1U2CCA233262-01
clinical_trial	NCT03095248	Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601)	23-Jul-21	Recruiting	1U2CCA233262-01
clinical_trial	NCT02523014	Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas	17-Aug-21	Suspended	1U2CCA233262-01
clinical_trial	NCT02831257	AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas	22-Dec-20	Completed	1U2CCA233262-01
clinical_trial	NCT03071874	Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas	20-Jan-21	"Active, not recruiting"	1U2CCA233262-01
clinical_trial	NCT02060188	"An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (CheckMate142)"	6-Nov-19	"Active, not recruiting"	1U01CA233056-01
clinical_trial	NCT02460198	Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)	22-Mar-21	Completed	1U01CA233056-01
clinical_trial	NCT03631641	Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy	15-May-20	"Active, not recruiting"	1U01CA233056-01
clinical_trial	NCT01461148	Vaccination Against MSI Colorectal Cancer	23-Jun-15	Completed	1U01CA233056-01
clinical_trial	NCT01461148	Vaccination Against MSI Colorectal Cancer	23-Jun-15	Completed	1U01CA233097-01
clinical_trial	NCT01885702	Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI	9-Dec-20	"Active, not recruiting"	1U01CA233056-01
clinical_trial	NCT02657005	TK216 in Patients With Relapsed or Refractory Ewing Sarcoma	26-May-21	Recruiting	3R01CA204915-02S1
clinical_trial	NCT00070109	Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors	14-Sep-18	Completed	3R01CA204915-02S1
clinical_trial	NCT03600649	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas	11-Aug-21	Recruiting	3R01CA204915-02S1
clinical_trial	NCT03600649	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas	11-Aug-21	Recruiting	1U54CA231641-01
clinical_trial	NCT01610570	Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma	2-Mar-18	Terminated	3R01CA204915-02S1
clinical_trial	NCT03637491	"A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors"	23-Jul-21	Terminated	1U01DE028233-01
clinical_trial	NCT03598270	Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)	13-Aug-21	Recruiting	1U01DE028233-01
clinical_trial	NCT02243579	Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome	20-Sep-19	Completed	2UM1CA154967-07
clinical_trial	NCT01522443	Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)	23-May-18	Terminated	1U01CA233046-01
clinical_trial	NCT01240538	Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors	13-May-14	Completed	1U01CA232488-01
clinical_trial	NCT01240538	Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors	13-May-14	Completed	1U54CA232561-01A1
clinical_trial	NCT01048892	"Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features"	30-Jan-14	Completed	1U01CA232488-01
clinical_trial	NCT01048892	"Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features"	30-Jan-14	Completed	1U54CA232561-01A1
clinical_trial	NCT02457845	HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors	8-Jul-21	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT02457845	HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors	8-Jul-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03043391	Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children	13-Jul-21	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT03043391	Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children	13-Jul-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02756845	Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors	19-Aug-21	Recruiting	1U01CA232488-01
clinical_trial	NCT02756845	Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors	19-Aug-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT00931931	HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors	21-Mar-18	Completed	1U01CA232488-01
clinical_trial	NCT00931931	HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors	21-Mar-18	Completed	1U54CA232561-01A1
clinical_trial	NCT01326104	Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (Re-MATCH)	11-Aug-21	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT01326104	Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (Re-MATCH)	11-Aug-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02932956	Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP)	8-Jan-21	Recruiting	1U01CA232488-01
clinical_trial	NCT02932956	Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP)	8-Jan-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03500991	HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors	15-Mar-21	Recruiting	1U01CA232488-01
clinical_trial	NCT03500991	HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors	15-Mar-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03638167	EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors	15-Mar-21	Recruiting	1U01CA232488-01
clinical_trial	NCT03638167	EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors	15-Mar-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02315612	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies	2-Aug-21	Recruiting	1U01CA232488-01
clinical_trial	NCT02315612	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies	2-Aug-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02772198	T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies	3-Nov-20	Recruiting	1U01CA232488-01
clinical_trial	NCT02772198	T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies	3-Nov-20	Recruiting	1U54CA232561-01A1
clinical_trial	NCT01555892	"Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (GRALE)"	23-Dec-20	Recruiting	1U01CA232488-01
clinical_trial	NCT01555892	"Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (GRALE)"	23-Dec-20	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02892695	PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma	6-Dec-16	Unknown	1U01CA232488-01
clinical_trial	NCT02892695	PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma	6-Dec-16	Unknown	1U54CA232561-01A1
clinical_trial	NCT02892695	PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma	6-Dec-16	Unknown	1U01CA239258-01
clinical_trial	NCT02573896	Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells	20-Jan-21	Recruiting	1U01CA232488-01
clinical_trial	NCT02573896	Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells	20-Jan-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02573896	Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells	20-Jan-21	Recruiting	1U01CA232491-01
clinical_trial	NCT02573896	Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells	20-Jan-21	Recruiting	1U01CA239258-01
clinical_trial	NCT02650648	Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma	5-Oct-20	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT02650648	Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma	5-Oct-20	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02650648	Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma	5-Oct-20	"Active, not recruiting"	1U01CA232491-01
clinical_trial	NCT02650648	Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma	5-Oct-20	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT03209869	Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2	5-Aug-21	Suspended	1U01CA232488-01
clinical_trial	NCT03209869	Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2	5-Aug-21	Suspended	1U54CA232561-01A1
clinical_trial	NCT03420963	"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors"	29-Apr-21	Recruiting	1U01CA232488-01
clinical_trial	NCT03420963	"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors"	29-Apr-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03420963	"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors"	29-Apr-21	Recruiting	1U01CA232491-01
clinical_trial	NCT03420963	"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors"	29-Apr-21	Recruiting	1U01CA239258-01
clinical_trial	NCT02100891	Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)	24-Mar-21	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT02100891	Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)	24-Mar-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02100891	Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)	24-Mar-21	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT01823198	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	4-Dec-20	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT01823198	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	4-Dec-20	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT01823198	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	4-Dec-20	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT01904136	"Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia"	10-Feb-21	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT01904136	"Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia"	10-Feb-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02809092	Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia	15-Oct-19	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT02809092	Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia	15-Oct-19	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02809092	Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia	15-Oct-19	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT01898793	Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	21-May-21	Recruiting	1U01CA232488-01
clinical_trial	NCT01898793	Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	21-May-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT01619761	NK Cells in Cord Blood Transplantation	11-Feb-20	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT01619761	NK Cells in Cord Blood Transplantation	11-Feb-20	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT01714739	A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors	14-Dec-20	Completed	1U54CA232561-01A1
clinical_trial	NCT01750580	Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor	22-Jul-15	Completed	1U54CA232561-01A1
clinical_trial	NCT02331875	Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity	4-Jan-17	Terminated	1U54CA232561-01A1
clinical_trial	NCT02141451	ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL	19-Feb-20	Completed	1U54CA232561-01A1
clinical_trial	NCT02393859	Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)	8-Dec-20	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02435849	Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed &lt; 6 Months Post All-HSCT. (ELIANA)	30-Jun-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02435849	Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed &lt; 6 Months Post All-HSCT. (ELIANA)	30-Jun-21	"Active, not recruiting"	1R01CA226983-01
clinical_trial	NCT02559778	Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN)	18-Nov-20	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03837899	Durvalumab and Tremelimumab for Pediatric Malignancies	3-Aug-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT04044378	Famitinib Plus Camrelizumab &amp; Famitinib Alone &amp; Famitinib Plus Ifosfamide in Advanced Osteosarcoma	19-May-20	Withdrawn	1U54CA232561-01A1
clinical_trial	NCT02311621	Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01	27-Apr-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02311621	Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01	27-Apr-21	Recruiting	1U54CA244438-01
clinical_trial	NCT03130959	An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908)	1-Apr-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03618381	EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults	19-Apr-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03618381	EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults	19-Apr-21	Recruiting	1UG3CA244687-01
clinical_trial	NCT03334305	Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (ACTION)	12-Aug-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03448393	CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	21-Jul-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT01192555	Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (ATOMIC)	10-Mar-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02502708	"Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors"	4-Jun-20	Completed	1U54CA232561-01A1
clinical_trial	NCT02502708	"Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors"	4-Jun-20	Completed	1U01CA224151-01
clinical_trial	NCT03703050	"Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)"	7-Jul-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03907488	Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma	19-Aug-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02789228	Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST)	25-Feb-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03396575	Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO)	13-Jul-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03911388	HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors	8-Jul-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03178032	"Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas"	16-Jul-20	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03178032	"Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas"	16-Jul-20	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02962167	Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT	30-Jun-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02444546	Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors	18-Aug-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03495921	Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma (VITA)	18-Aug-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT00790413	Haploidentical Stem Cell Transplantation in Neuroblastoma	21-Feb-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02793466	Durvalumab in Pediatric and Adolescent Patients	30-Jan-19	Unknown	1U54CA232561-01A1
clinical_trial	NCT01860937	T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia	6-Jul-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03006848	A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma	11-Mar-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT00634231	A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors	27-Jan-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02511132	A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma	4-Feb-21	Completed	1U54CA232561-01A1
clinical_trial	NCT03299309	PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma (PRiME)	25-May-21	Suspended	1U54CA232561-01A1
clinical_trial	NCT02028455	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	29-Jan-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02028455	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	29-Jan-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT03643276	Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017	7-Jul-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03244306	A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)	19-Jan-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03244306	A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)	19-Jan-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT03186118	Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia	25-Mar-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03605589	Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma	1-Apr-21	Withdrawn	1U54CA232561-01A1
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	24-May-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	24-May-21	Recruiting	1U01CA247548-01
clinical_trial	NCT00902044	Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma	1-Sep-20	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03769467	Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)	3-Feb-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02960230	H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas	19-May-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT01700946	Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma	4-May-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT01700946	Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma	4-May-21	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT01169584	Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients	21-Jan-16	Completed	1U54CA232561-01A1
clinical_trial	NCT03359018	Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (APFAO)	19-May-20	Completed	1U54CA232561-01A1
clinical_trial	NCT02403778	Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma	23-Sep-20	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	14-Jan-21	"Active, not recruiting"	1U54CA244711-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	14-Jan-21	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	14-Jan-21	"Active, not recruiting"	3P30CA013696-45S1
clinical_trial	NCT01747486	Dose Optimization Trial of CD19 Redirected Autologous T Cells	30-Aug-19	Completed	1U54CA244711-01
clinical_trial	NCT01626495	Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)	23-Mar-20	Completed	1U54CA244711-01
clinical_trial	NCT01626495	Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)	23-Mar-20	Completed	1R01CA226983-01
clinical_trial	NCT01029366	CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy	26-Jun-19	Completed	1U54CA244711-01
clinical_trial	NCT02640209	Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)	7-May-20	Terminated	1U54CA244711-01
clinical_trial	NCT02675439	Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	9-Jul-20	"Active, not recruiting"	1U01DE029255-01
clinical_trial	NCT03172936	Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	24-Feb-21	Completed	1U01DE029255-01
clinical_trial	NCT03172936	Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	24-Feb-21	Completed	1U54CA244719-01
clinical_trial	NCT03010176	Study of MK-1454 Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	21-Apr-21	"Active, not recruiting"	1U01DE029255-01
clinical_trial	NCT03010176	Study of MK-1454 Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	21-Apr-21	"Active, not recruiting"	1U54CA244719-01
clinical_trial	NCT03635164	Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma	20-May-21	"Active, not recruiting"	1U01DE029255-01
clinical_trial	NCT01811992	Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma	10-Feb-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT00002824	Gene Therapy in Treating Patients With Primary Brain Tumors	13-Mar-19	Completed	1U01CA224160-01
clinical_trial	NCT02017717	A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143)	19-Apr-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02311920	Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma	6-Jul-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02414165	The Toca 5 Trial: Toca 511 &amp; Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (Toca5)	7-Feb-20	Terminated	1U01CA224160-01
clinical_trial	NCT00805376	DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas	16-Jul-18	Completed	1U01CA224160-01
clinical_trial	NCT01472003	An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types	14-Jan-13	Completed	1U01CA224160-01
clinical_trial	NCT01255657	A Study of ABT-806 in Subjects With Advanced Solid Tumor Types	21-Nov-17	Completed	1U01CA224160-01
clinical_trial	NCT01406119	An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors	27-Jan-17	Completed	1U01CA224160-01
clinical_trial	NCT02381886	A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	26-Jul-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02977689	Trial of IDH305 in IDH1 Mutant Grade II or III Glioma	20-Dec-17	Withdrawn	1U01CA224160-01
clinical_trial	NCT02253212	Safety of BBB Opening With the SonoCloud (SONOCLOUD)	12-Oct-18	Completed	1U01CA224160-01
clinical_trial	NCT02573324	A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)	24-May-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02343406	Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE-2)	22-May-20	Completed	1U01CA224160-01
clinical_trial	NCT00458601	Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme (ACT III)	16-Jan-18	Completed	1U01CA224160-01
clinical_trial	NCT03899857	Pembrolizumab for Newly Diagnosed Glioblastoma (PERGOLA)	16-Dec-20	Recruiting	1U01CA224160-01
clinical_trial	NCT03726515	CART-EGFRvIII + Pembrolizumab in GBM	3-Mar-21	Completed	1U01CA224160-01
clinical_trial	NCT03726515	CART-EGFRvIII + Pembrolizumab in GBM	3-Mar-21	Completed	1U01CA239258-01
clinical_trial	NCT02661282	Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma	22-Jul-20	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT01491893	PVSRIPO for Recurrent Glioblastoma (GBM) (PVSRIPO)	12-Jan-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT01130142	A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer	6-Mar-17	Completed	1U01CA224193-01
clinical_trial	NCT01130142	A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer	6-Mar-17	Completed	1U54CA224083-01
clinical_trial	NCT01850628	NSABP Biospecimen Discovery Project	10-Sep-20	"Active, not recruiting"	1U54CA233223-01
clinical_trial	NCT02228096	Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)	23-Nov-20	Completed	1R01CA226983-01
clinical_trial	NCT02030847	Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia	30-Aug-19	Completed	1R01CA226983-01
clinical_trial	NCT01514201	"Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas"	13-Aug-19	Completed	2UM1CA081457-21
clinical_trial	NCT00770471	"ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"	27-Jun-18	Completed	2UM1CA081457-21
clinical_trial	NCT02484443	Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma	5-Aug-21	"Active, not recruiting"	1U01CA232491-01
clinical_trial	NCT02484443	Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma	5-Aug-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT01419834	Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors	25-Aug-20	"Active, not recruiting"	1U01CA232491-01
clinical_trial	NCT01662804	Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors	27-May-21	Completed	1U01CA232491-01
clinical_trial	NCT02159443	Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody	5-Nov-20	Completed	1U01CA232491-01
clinical_trial	NCT00743496	"A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma"	17-Aug-17	Completed	1U01CA232491-01
clinical_trial	NCT02982941	Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors	30-Jan-20	Completed	1U01CA232491-01
clinical_trial	NCT00582608	Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9	1-Mar-17	Terminated	1U01CA232491-01
clinical_trial	NCT02173093	Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma	29-Jan-19	Unknown	1U01CA232491-01
clinical_trial	NCT03860207	"Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers"	25-May-21	Recruiting	1U01CA232491-01
clinical_trial	NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	10-Dec-19	Terminated	1U01CA239258-01
clinical_trial	NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	10-Dec-19	Terminated	1U54CA244438-01
clinical_trial	NCT03294954	GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2)	15-Jan-21	Recruiting	1U01CA239258-01
clinical_trial	NCT03579927	"CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma"	29-Jan-20	Withdrawn	1U01CA239258-01
clinical_trial	NCT03056339	Umbilical &amp; Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies	19-Jul-21	Recruiting	1U01CA239258-01
clinical_trial	NCT03545815	Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.	10-Aug-20	Recruiting	1U01CA239258-01
clinical_trial	NCT02414269	Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin	1-Apr-21	Recruiting	1U01CA239258-01
clinical_trial	NCT04003649	IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma	9-Dec-20	Recruiting	1U01CA239258-01
clinical_trial	NCT02498912	Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors	8-Feb-21	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT02498912	Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors	8-Feb-21	"Active, not recruiting"	1U54CA244438-01
clinical_trial	NCT04093648	T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)	20-May-20	Withdrawn	1U01CA239258-01
clinical_trial	NCT03721068	Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma	7-Jul-21	Recruiting	1U01CA239258-01
clinical_trial	NCT02569723	Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy	30-Mar-21	Completed	1U54CA233306-01
clinical_trial	NCT02255461	"Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors"	2-Mar-21	Terminated	2UM1CA081457-21
clinical_trial	NCT02255461	"Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors"	2-Mar-21	Terminated	1U01CA224160-01
clinical_trial	NCT03387020	Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors	27-May-20	Completed	1U01CA224160-01
clinical_trial	NCT03355794	A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)	26-Jan-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02644460	Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors (AflacST1501)	4-Mar-21	Recruiting	1U01CA224160-01
clinical_trial	NCT02717455	Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma (PBTC-047)	17-Mar-21	Recruiting	1U01CA224160-01
clinical_trial	NCT03632317	A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas	19-Aug-19	Withdrawn	1U01CA224160-01
clinical_trial	NCT03566199	MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma (PNOC015)	13-Apr-21	Completed	1U01CA224160-01
clinical_trial	NCT00058474	Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer	23-Mar-16	Unknown	1U01CA232859-01
clinical_trial	NCT03184571	Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC	29-May-20	Recruiting	1U24CA224316-01
clinical_trial	NCT00480363	QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression (QUIREDEX)	31-Jul-13	Completed	1U01CA244291-01
clinical_trial	NCT01169337	Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma	18-May-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02681302	Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001)	4-May-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02252263	A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma	1-Nov-17	Completed	1U01CA244291-01
clinical_trial	NCT02654132	An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)	14-Jul-20	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02289222	1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma	5-Nov-19	Terminated	1U01CA244291-01
clinical_trial	NCT02036502	A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)	8-Apr-21	Terminated	1U01CA244291-01
clinical_trial	NCT02726581	"An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602)"	6-Aug-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02076009	"A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma"	9-Aug-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02136134	Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	11-Aug-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02431208	A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)	2-Apr-21	Completed	1U01CA244291-01
clinical_trial	NCT01592370	An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma	18-Jun-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT03357952	"A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma"	28-Jan-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT03111992	"Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma"	9-Sep-20	Completed	1U01CA244291-01
clinical_trial	NCT03015922	Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma (MUKeleven)	22-Jan-20	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02514382	"Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma"	3-May-19	Unknown	1U01CA244291-01
clinical_trial	NCT02101944	Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma	13-Aug-21	Recruiting	1U01CA244291-01
clinical_trial	NCT00450814	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma	16-Dec-19	Completed	1U01CA244291-01
clinical_trial	NCT02192775	UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus	19-Oct-20	Completed	1U01CA244291-01
clinical_trial	NCT03017820	"VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma"	12-Jul-21	Suspended	1U01CA244291-01
clinical_trial	NCT01858558	Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma	29-Jun-20	Completed	1U01CA244291-01
clinical_trial	NCT02728102	Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)	22-Jun-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT03090659	LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)	23-Feb-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT03093168	BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma	27-Feb-19	Unknown	1U01CA244291-01
clinical_trial	NCT03288493	P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)	12-Nov-20	Recruiting	1U01CA244291-01
clinical_trial	NCT03318861	Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma	28-Jun-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02658929	Study of bb2121 in Multiple Myeloma	4-Dec-20	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02658929	Study of bb2121 in Multiple Myeloma	4-Dec-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02215967	Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma	8-Oct-19	Completed	1U01CA244291-01
clinical_trial	NCT03672318	Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma	30-Jun-21	Recruiting	1U01CA244291-01
clinical_trial	NCT03958656	T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma	19-Apr-21	Completed	1U01CA244291-01
clinical_trial	NCT03455972	Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT	19-May-21	Recruiting	1U01CA244291-01
clinical_trial	NCT03502577	BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	2-Aug-21	Suspended	1U01CA244291-01
clinical_trial	NCT03502577	BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	2-Aug-21	Suspended	1U01CA247548-01
clinical_trial	NCT02304458	Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas	9-Jun-21	"Active, not recruiting"	5UM1CA228823-03
clinical_trial	NCT02927769	"A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment (CheckMate 744)"	11-Jun-20	Recruiting	5UM1CA228823-03
clinical_trial	NCT02843165	Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease	25-Jan-21	Recruiting	1U01DE028227-01
clinical_trial	NCT00648648	"A Dose Escalation Study of MK-1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)"	5-Apr-19	Completed	1U01CA233084-01
clinical_trial	NCT02936609	Assessing Community Cancer Care After Insurance ExpanSionS (ACCESS)	19-Aug-20	"Active, not recruiting"	1P50CA244289-01
clinical_trial	NCT03545763	Evaluating Control of Hypertension - Effect of Social Determinants (ECHOES)	23-Mar-21	"Active, not recruiting"	1P50CA244289-01
clinical_trial	NCT03433183	SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors	18-Sep-20	Recruiting	1UG3CA244687-01
clinical_trial	NCT02008877	SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)	15-May-19	Completed	1UG3CA244687-01
clinical_trial	NCT02584647	PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors (PLX3397)	2-Jun-21	Recruiting	1UG3CA244687-01
clinical_trial	NCT03009201	Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery	15-Jun-21	"Active, not recruiting"	1UG3CA244687-01
clinical_trial	NCT02691026	"A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery"	23-Jun-21	Terminated	1UG3CA244687-01
clinical_trial	NCT02834013	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	19-Aug-21	Recruiting	1UG3CA244687-01
clinical_trial	NCT04222413	Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors	23-Jul-21	Recruiting	1UG3CA244687-01
clinical_trial	NCT03880123	Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma	27-Nov-20	Withdrawn	1UG3CA244687-01
clinical_trial	NCT03665285	A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors	18-Aug-21	Recruiting	1U01CA232491-01
clinical_trial	NCT03615040	Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) (COPD-ST2OP)	25-Feb-21	Completed	1U01CA232491-01
clinical_trial	NCT02221739	Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)	11-May-20	Completed	1U01CA233102-01
clinical_trial	NCT03958383	"IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma"	27-Nov-20	Recruiting	1U01CA233102-01
clinical_trial	NCT03958383	"IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma"	27-Nov-20	Recruiting	1U54CA232568-01
clinical_trial	NCT00879866	EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)	23-Jun-14	Completed	1U01CA233102-01
clinical_trial	NCT03275597	Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition	13-Aug-21	"Active, not recruiting"	1U01CA233102-01
clinical_trial	NCT01964300	Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery	24-Feb-20	Terminated	2UM1CA081457-21
clinical_trial	NCT03212274	"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations"	9-Aug-21	Recruiting	1U01CA224146-01
clinical_trial	NCT02588105	Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (AToM)	18-Aug-21	"Active, not recruiting"	1U01CA224146-01
clinical_trial	NCT02588105	Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (AToM)	18-Aug-21	"Active, not recruiting"	1U54CA244719-01
clinical_trial	NCT03462342	Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI)	27-Jan-21	Recruiting	1U01CA224146-01
clinical_trial	NCT04149145	Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer (PARP)	6-Jul-21	Not yet recruiting	1U01CA224146-01
clinical_trial	NCT03669601	AZD6738 &amp; Gemcitabine as Combination Therapy (ATRiUM)	4-Jun-21	Recruiting	1U01CA224146-01
clinical_trial	NCT04095273	"Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug"	5-Aug-21	Recruiting	1U01CA224146-01
clinical_trial	NCT03057145	Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors	10-Jun-21	Completed	1U01CA224146-01
clinical_trial	NCT02632448	A Study of LY2880070 in Participants With Advanced or Metastatic Cancer	16-Sep-20	Recruiting	1U01CA224146-01
clinical_trial	NCT03495323	"A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors"	15-Apr-21	Completed	1U01CA224146-01
clinical_trial	NCT03724890	Study of Avelumab-M3814 Combinations	17-Aug-21	Recruiting	1U01CA224146-01
clinical_trial	NCT03770689	Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer	24-Jun-21	"Active, not recruiting"	1U01CA224146-01
clinical_trial	NCT04197713	"Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study"	18-Jun-21	Recruiting	1U01CA224146-01
clinical_trial	NCT03012477	CISPLATIN + AZD-1775 In Breast Cancer	28-Jun-21	Completed	1U01CA224146-01
clinical_trial	NCT02617277	"Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours"	16-Jun-21	"Active, not recruiting"	1U01CA224146-01
clinical_trial	NCT00238238	Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab	15-Mar-17	Completed	1U01CA233046-01
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	16-Aug-18	"Active, not recruiting"	1U2CCA233303-01
clinical_trial	NCT01358721	Phase I Biomarker Study (BMS-936558)	29-Oct-20	Completed	1U24CA224331-01
clinical_trial	NCT01354431	BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)	9-Sep-20	"Active, not recruiting"	1U24CA224331-01
clinical_trial	NCT01668784	Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)	24-Aug-20	"Active, not recruiting"	1U24CA224331-01
clinical_trial	NCT02451423	Neoadjuvant Atezolizumab in Localized Bladder Cancer	30-Mar-20	Recruiting	1U01CA244452-01
clinical_trial	NCT03225105	M3541 in Combination With Radiotherapy in Subjects With Solid Tumors	14-Sep-20	Completed	1U54CA244719-01
clinical_trial	NCT02494583	Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)	10-Mar-21	"Active, not recruiting"	1U54CA244719-01
clinical_trial	NCT03189719	First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)	6-Jul-21	"Active, not recruiting"	1U54CA244719-01
clinical_trial	NCT01120288	"A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases"	5-Jul-18	Completed	1U01DE029255-01
clinical_trial	NCT00466583	Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma	7-Jul-11	Completed	1U01DE029255-01
clinical_trial	NCT02550327	"Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer"	22-Jun-21	Completed	1U54CA224083-01
clinical_trial	NCT03328078	A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies	5-May-21	Recruiting	1U54CA224083-01
clinical_trial	NCT01543698	A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors	10-May-21	"Active, not recruiting"	1U54CA224070-01
clinical_trial	NCT02159066	"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma (LOGIC-2)"	15-Jun-21	"Active, not recruiting"	1U54CA224070-01
clinical_trial	NCT03765918	Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)	13-Aug-21	Recruiting	3U24CA237719-02S1
clinical_trial	NCT03153462	Axicabtagene Ciloleucel Expanded Access Study (ZUMA-9)	17-May-21	Approved for marketing	1U01CA247576-01
clinical_trial	NCT03059485	DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission	22-Oct-20	Recruiting	1U01CA233084-01
clinical_trial	NCT04025216	A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers	29-Apr-21	Recruiting	1U01CA233084-01
clinical_trial	NCT01415882	Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib	8-Apr-21	Recruiting	1U54CA224018-01
clinical_trial	NCT04358276	"Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study"	16-Feb-21	Recruiting	1R01CA249460-01
clinical_trial	NCT02215850	Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours	17-May-16	Completed	1U2CCA233280-01
clinical_trial	NCT03450018	A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01)	15-Mar-21	Recruiting	1U2CCA233280-01
clinical_trial	NCT03375086	A Study of APX3330 in Patients With Advanced Solid Tumors (APX3330)	7-Sep-20	Completed	1U2CCA233280-01
clinical_trial	NCT03447769	Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T&gt;5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A)	9-Aug-21	Recruiting	1U2CCA233238-01
clinical_trial	NCT03631199	Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)	16-Aug-21	"Active, not recruiting"	1U2CCA233238-01
clinical_trial	NCT03300817	MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer	2-Aug-21	Recruiting	1U2CCA233238-01
clinical_trial	NCT03634241	"Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study"	1-Jun-21	Recruiting	1U2CCA233238-01
clinical_trial	NCT02927301	A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)	17-May-21	"Active, not recruiting"	1U2CCA233238-01
clinical_trial	NCT02716038	"Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC"	15-Apr-21	"Active, not recruiting"	1U2CCA233238-01
clinical_trial	NCT03393936	Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma	7-Apr-20	"Active, not recruiting"	1U54CA244438-01
clinical_trial	NCT02541370	Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133	17-Dec-19	Completed	1U54CA244438-01
clinical_trial	NCT02862704	A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)	11-Aug-16	Unknown	1U54CA244438-01
clinical_trial	NCT04045847	CD147-CART Cells in Patients With Recurrent Malignant Glioma.	7-May-20	Recruiting	1U54CA244438-01
clinical_trial	NCT02830724	Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers	29-Jan-21	Suspended	1U54CA244438-01
clinical_trial	NCT03198052	HER2/Mesothelin/Lewis-Y/PSCA/MUC1/GPC3/AXL/EGFR/B7-H3/Claudin18.2-CAR-T Cells Immunotherapy Against Cancers	1-Dec-20	Recruiting	1U54CA244438-01
clinical_trial	NCT01373047	CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells (HITM)	30-Jul-13	Completed	1U54CA244438-01
clinical_trial	NCT03159819	Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma	12-Mar-18	Recruiting	1U54CA244438-01
clinical_trial	NCT02331693	CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR	6-Jan-15	Unknown	1U54CA244438-01
clinical_trial	NCT02915445	EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer	8-Apr-19	Recruiting	1U54CA244438-01
clinical_trial	NCT03423992	Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas	15-Jun-21	Recruiting	1U54CA244438-01
clinical_trial	NCT01722149	Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma	7-Aug-19	Completed	1U54CA244438-01
clinical_trial	NCT00019136	Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer	29-Apr-15	Completed	1U54CA244438-01
clinical_trial	NCT00085930	Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients (NESTLES)	8-Jan-21	"Active, not recruiting"	1U54CA244438-01
clinical_trial	NCT02959151	A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy	8-Nov-16	Unknown	1U54CA244438-01
clinical_trial	NCT00730613	Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma	9-Oct-17	Completed	1U54CA244438-01
clinical_trial	NCT02442297	T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (iCAR)	10-Mar-21	Recruiting	1U54CA244438-01
clinical_trial	NCT02930993	Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors	12-Oct-16	Unknown	1U54CA244438-01
clinical_trial	NCT01837602	cMet CAR RNA T Cells Targeting Breast Cancer	19-Oct-18	Completed	1U54CA244438-01
clinical_trial	NCT02617134	CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor	6-Dec-16	Unknown	1U54CA244438-01
clinical_trial	NCT01929239	Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning	17-Jun-16	Suspended	1U54CA244438-01
clinical_trial	NCT02706392	Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	8-Jul-21	Recruiting	1U54CA244438-01
clinical_trial	NCT02706392	Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	8-Jul-21	Recruiting	1U01CA247548-01
clinical_trial	NCT03278340	Using Technology to Scale-Up an Occupational Sun Protection Policy Program (SSW-T)	9-Jul-21	Enrolling by invitation	1R01CA210259-01A1
clinical_trial	NCT02181413	A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant	9-Mar-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT00114101	Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant	23-Jun-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT01338012	Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (mCRPC)	5-Jun-17	Terminated	1U01CA233100-01
clinical_trial	NCT01981122	A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer	24-Oct-18	Completed	1U01CA233100-01
clinical_trial	NCT00779402	PROvenge Treatment and Early Cancer Treatment (PROTECT)	29-Jan-18	Completed	1U01CA233100-01
clinical_trial	NCT04071366	A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy	13-Apr-21	Recruiting	1R01CA226983-01
clinical_trial	NCT01560923	Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer	3-Apr-20	Completed	1U01CA224151-01
clinical_trial	NCT02073123	Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma	5-Jun-20	Completed	1U01CA224151-01
clinical_trial	NCT02835729	A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia	4-Jun-20	Completed	1U01CA224151-01
clinical_trial	NCT02052648	Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors	28-May-20	Completed	1U01CA224151-01
clinical_trial	NCT03301636	A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)	5-Jun-20	Terminated	1U01CA224151-01
clinical_trial	NCT02502648				1U01CA224151-01
clinical_trial	NCT00720785	Natural Killer Cells and Bortezomib to Treat Cancer	4-Aug-21	Completed	1U01CA239258-01
clinical_trial	NCT02185781	Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)	6-Aug-18	Unknown	1U01CA239258-01
clinical_trial	NCT02271711	Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors	2-Sep-20	Completed	1U01CA239258-01
clinical_trial	NCT02507154	Reactivating NK Cells in Treating Refractory Head and Neck Cancer (NKEXPHNC)	21-Aug-18	Unknown	1U01CA239258-01
clinical_trial	NCT02661685	Safety Study of Adoptive Transfer of Autologous IKDC-like Cells	18-Feb-21	Completed	1U01CA239258-01
clinical_trial	NCT03003728	2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)	10-Jul-20	Withdrawn	1U01CA239258-01
clinical_trial	NCT03410368	NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.	17-Jul-18	Unknown	1U01CA239258-01
clinical_trial	NCT03415100	Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours	1-Aug-18	Unknown	1U01CA239258-01
clinical_trial	NCT03499834	A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy (IVY03)	16-Apr-20	Completed	1U01CA239258-01
clinical_trial	NCT03592706	Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy	16-Apr-20	Recruiting	1U01CA239258-01
clinical_trial	NCT03662477	Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation	6-Dec-19	Recruiting	1U01CA239258-01
clinical_trial	NCT03941262	Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy	3-May-21	Recruiting	1U01CA239258-01
clinical_trial	NCT03958097	A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer	21-May-19	Unknown	1U01CA239258-01
clinical_trial	NCT00900809	QUILT-3.018: Neukoplast&#8482; (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia	13-Jun-18	Completed	1U01CA239258-01
clinical_trial	NCT00990717	Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies	23-Jun-16	Completed	1U01CA239258-01
clinical_trial	NCT01040026	Expanded Natural Killer (NK) Cells for Multiple Myeloma Study	15-Nov-19	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT01729091	"Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma"	14-Jul-21	Recruiting	1U01CA239258-01
clinical_trial	NCT01807468	Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors	18-Sep-18	Unknown	1U01CA239258-01
clinical_trial	NCT02229266	Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML (HINKL)	16-Aug-21	Terminated	1U01CA239258-01
clinical_trial	NCT02409576	"Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas (NKEXPSARC)"	16-Apr-19	Unknown	1U01CA239258-01
clinical_trial	NCT02452697	"Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT (NK-DCI)"	25-Feb-21	Recruiting	1U01CA239258-01
clinical_trial	NCT02465957	QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)	14-Aug-20	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT02727803	"Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma"	7-Aug-20	Recruiting	1U01CA239258-01
clinical_trial	NCT02742727	CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma	6-Dec-16	Unknown	1U01CA239258-01
clinical_trial	NCT02763475	NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents	5-Oct-20	Completed	1U01CA239258-01
clinical_trial	NCT02944162	CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML	6-Dec-16	Unknown	1U01CA239258-01
clinical_trial	NCT02955550	"A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)"	22-Jul-20	Completed	1U01CA239258-01
clinical_trial	NCT03019640	"Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma"	16-Aug-21	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT03027128	QUILT-3.028: Study of haNK&#8482; for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors	28-Aug-19	Completed	1U01CA239258-01
clinical_trial	NCT03068819	Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant	8-Apr-21	Recruiting	1U01CA239258-01
clinical_trial	NCT03136406	QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy	12-Aug-20	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT03167164	QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy	19-Mar-21	Withdrawn	1U01CA239258-01
clinical_trial	NCT03167177	QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy	19-Mar-21	Withdrawn	1U01CA239258-01
clinical_trial	NCT03169738	QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors	19-Mar-21	Withdrawn	1U01CA239258-01
clinical_trial	NCT03169764	QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy	19-Mar-21	Withdrawn	1U01CA239258-01
clinical_trial	NCT03169777	QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC	18-Mar-21	Withdrawn	1U01CA239258-01
clinical_trial	NCT03169790	QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL	18-Mar-21	Withdrawn	1U01CA239258-01
clinical_trial	NCT03175666	QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy	18-Mar-21	Withdrawn	1U01CA239258-01
clinical_trial	NCT03197571	QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy	18-Mar-21	Withdrawn	1U01CA239258-01
clinical_trial	NCT03197584	QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy	18-Mar-21	Withdrawn	1U01CA239258-01
clinical_trial	NCT03300492	Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS	2-Dec-20	Recruiting	1U01CA239258-01
clinical_trial	NCT03329248	QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy	11-Aug-20	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT03383978	Intracranial Injection of NK-92/5.28.z Cells in Patients With Recurrent HER2-positive Glioblastoma (CAR2BRAIN)	25-Sep-20	Recruiting	1U01CA239258-01
clinical_trial	NCT03387085	QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.	17-May-19	Unknown	1U01CA239258-01
clinical_trial	NCT03387098	QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy	16-Jul-19	Unknown	1U01CA239258-01
clinical_trial	NCT03387111	QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed	11-Aug-20	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT03539406	Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients (INTRO)	16-Sep-19	Recruiting	1U01CA239258-01
clinical_trial	NCT03554109	QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (TNBC)	14-May-19	Withdrawn	1U01CA239258-01
clinical_trial	NCT03563144	QUILT-3.088: NANT Pancreatic Cancer Vaccine	18-Mar-21	Withdrawn	1U01CA239258-01
clinical_trial	NCT03563157	QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine	18-Sep-20	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT03563170	QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine	18-Mar-21	Withdrawn	1U01CA239258-01
clinical_trial	NCT03574649	"QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer"	28-Aug-19	Withdrawn	1U01CA239258-01
clinical_trial	NCT03586869	QUILT-3.080: NANT Pancreatic Cancer Vaccine	16-Jul-19	Unknown	1U01CA239258-01
clinical_trial	NCT03647423	QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.	19-Mar-21	Withdrawn	1U01CA239258-01
clinical_trial	NCT03656705	CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma	8-Apr-21	Enrolling by invitation	1U01CA239258-01
clinical_trial	NCT03669172	Efectiveness of Donor IL-15-stimulated NK Cells Post Transplant Infusion in in Acute Leukemia	26-Feb-20	Recruiting	1U01CA239258-01
clinical_trial	NCT03778619	MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin	28-Jul-20	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT03821519	Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant (Haplo-CIK)	31-Jan-19	Recruiting	1U01CA239258-01
clinical_trial	NCT03853317	"QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy"	18-Mar-21	Recruiting	1U01CA239258-01
clinical_trial	NCT03937895	Allogeneic NK Cell (&quot;SMT-NK&quot;) in Combination With Pembrolizumab in Advanced Biliary Tract Cancer	18-Jan-20	Unknown	1U01CA239258-01
clinical_trial	NCT03940833	Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM	7-May-19	Recruiting	1U01CA239258-01
clinical_trial	NCT04162158	Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma	14-Nov-19	Recruiting	1U01CA239258-01
clinical_trial	NCT04309084	Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma	19-Apr-21	Recruiting	1U01CA239258-01
clinical_trial	NCT04310592	Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01)	2-Mar-21	Recruiting	1U01CA239258-01
clinical_trial	NCT00625729	"Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia"	28-Dec-17	Terminated	1U01CA239258-01
clinical_trial	NCT00877110	Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma	10-Jan-19	Completed	1U01CA239258-01
clinical_trial	NCT01576692	"Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma"	15-Nov-18	Completed	1U01CA239258-01
clinical_trial	NCT02845999	Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab (NK-EGFR01)	27-Jul-16	Completed	1U01CA239258-01
clinical_trial	NCT03242603	Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells (NKEXPGD2)	30-Mar-18	Unknown	1U01CA239258-01
clinical_trial	NCT03554889	Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells	13-Jun-18	Unknown	1U01CA239258-01
clinical_trial	NCT04074746	Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas	3-Jun-21	Recruiting	1U01CA239258-01
clinical_trial	NCT04211675	"NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab (STING)"	1-Apr-21	Not yet recruiting	1U01CA239258-01
clinical_trial	NCT04245722	FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies	10-Aug-21	Recruiting	1U01CA239258-01
clinical_trial	NCT04106817	Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus	14-Jan-20	Completed	1U2CCA233195-01
clinical_trial	NCT04106817	Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus	14-Jan-20	Completed	1U2CCA233238-01
clinical_trial	NCT04514341	Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up	14-Aug-20	Not yet recruiting	1UG3CA233229-01
clinical_trial	NCT02840058	Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1 (ITHER)	2-Aug-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT04302675	Adapting Motivational Interviewing for Maternal Immunizations (MI4MI) (MI4MI)	26-Jul-21	"Active, not recruiting"	1P50CA244688-01
clinical_trial	NCT02066181	Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis	16-Jun-21	"Active, not recruiting"	1U01CA233046-01
clinical_trial	NCT03077477	Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers	14-Jun-18	Withdrawn	1U01CA232488-01
clinical_trial	NCT02369874	Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)	10-Feb-21	Completed	1U01DE029188-01
clinical_trial	NCT00404339	Vaccine Therapy in Treating Patients With Head and Neck Cancer	18-Apr-16	Completed	1U01DE029188-01
clinical_trial	NCT00257738	0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck	17-Oct-19	Completed	1U01DE029188-01
clinical_trial	NCT02426892	Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors	17-Feb-20	"Active, not recruiting"	1U01DE029188-01
clinical_trial	NCT01147991	Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer	28-Feb-12	Completed	1U01DE029188-01
clinical_trial	NCT03821272	A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients	13-May-21	Recruiting	1U01DE029188-01
clinical_trial	NCT02002182	"ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer"	2-Jul-21	"Active, not recruiting"	1U01DE029188-01
clinical_trial	NCT02865135	"Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer"	19-Jul-21	"Active, not recruiting"	1U01DE029188-01
clinical_trial	NCT03260023	Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers	29-Jun-21	Recruiting	1U01DE029188-01
clinical_trial	NCT03418480	HPV Anti-CD40 RNA Vaccine (HARE-40)	6-May-21	"Active, not recruiting"	1U01DE029188-01
clinical_trial	NCT04369937	HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for &quot;Intermediate Risk&quot; HPV-16-associated Head and Neck Squamous Cell Carcinoma	22-Oct-20	Recruiting	1U01DE029188-01
clinical_trial	NCT02544880	PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC	15-Jun-21	Completed	1U01DE029188-01
clinical_trial	NCT04247282	Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection	9-Jun-21	Suspended	1U01DE029188-01
clinical_trial	NCT02999646	Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC	30-Mar-21	Recruiting	1U01DE029188-01
clinical_trial	NCT03568058	Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers	9-Dec-20	"Active, not recruiting"	1U01DE029188-01
clinical_trial	NCT04266730	Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC)	8-Jul-21	Not yet recruiting	1U01DE029188-01
clinical_trial	NCT03689192	Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors	12-Feb-20	Recruiting	1U01DE029188-01
clinical_trial	NCT00019110	Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer	29-Apr-15	Completed	1U01DE029188-01
clinical_trial	NCT00019331	Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors	20-Jun-13	Completed	1U01DE029188-01
clinical_trial	NCT00021424	Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer	30-Apr-15	Completed	1U01DE029188-01
clinical_trial	NCT00027534	Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer	8-Sep-14	Completed	1U01DE029188-01
clinical_trial	NCT01462838	Immune Therapy of HPV-induced Cancers	23-Jun-15	Completed	1U01DE029188-01
clinical_trial	NCT01998542	Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (HNC)	23-Jan-20	Completed	1U01DE029188-01
clinical_trial	NCT02163057	Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma	22-Jan-21	Completed	1U01DE029188-01
clinical_trial	NCT02291055	Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer	19-Feb-20	"Active, not recruiting"	1U01DE029188-01
clinical_trial	NCT02526316	Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers (VICORYX-2)	2-Jul-17	Completed	1U01DE029188-01
clinical_trial	NCT03162224	Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer	27-Apr-21	Completed	1U01DE029188-01
clinical_trial	NCT01684150	"A Phase 1, Open-Label, Dose-Escalation &amp; Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK &amp; PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving"	4-Aug-16	Completed	5R01CA176745-09
clinical_trial	NCT03701295	"Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement"	24-Mar-21	Completed	5R01CA176745-09
clinical_trial	NCT03724084	Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement	3-Jun-21	Recruiting	5R01CA176745-09
clinical_trial	NCT04065399	A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)	6-May-21	Recruiting	5R01CA176745-09
clinical_trial	NCT04067336	First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia	5-Aug-21	Recruiting	5R01CA176745-09
clinical_trial	NCT02698176	A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)	27-Jan-21	Terminated	5R01CA176745-09
clinical_trial	NCT02698189	A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)	13-Jul-21	"Active, not recruiting"	5R01CA176745-09
clinical_trial	NCT02308761	A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome	11-Dec-17	Completed	5R01CA176745-09
clinical_trial	NCT03068351	Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma	7-Feb-20	Completed	5R01CA176745-09
clinical_trial	NCT03292172	"A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer"	6-Nov-20	Terminated	5R01CA176745-09
clinical_trial	NCT03255096	"A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6"	28-Jan-21	Completed	5R01CA176745-09
clinical_trial	NCT04320238	Experimental Trial of rhIFN&#945; Nasal Drops to Prevent 2019-nCOV in Medical Staff	31-Mar-20	Recruiting	1U01CA224348-01
clinical_trial	NCT03019003	Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients	1-Dec-20	Recruiting	1U01DE029188-01
clinical_trial	NCT03525795	ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors	11-Jan-21	Completed	1U01DE029188-01
clinical_trial	NCT03854474	Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma	4-Aug-21	Recruiting	1U01DE029188-01
clinical_trial	NCT01693562	A Phase 1/2 Study to Evaluate MEDI4736	13-May-21	Completed	1U01CA233100-01
clinical_trial	NCT01970358	A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma	9-Dec-20	Completed	1U24CA224331-01
clinical_trial	NCT03125239	Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia	30-Jun-20	Completed	3R01CA204396-02S1
clinical_trial	NCT03465540	"Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies"	18-Mar-21	Terminated	1U54CA224019-01
clinical_trial	NCT03063632	Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S&#233;zary Syndrome and Advanced Synovial Sarcoma	14-May-21	"Active, not recruiting"	2UM1CA154967-07
clinical_trial	NCT01495598	Pomalidomide for Kaposi Sarcoma in People With or Without HIV	29-Jul-21	"Active, not recruiting"	2UM1CA154967-07
clinical_trial	NCT02659930	Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma	11-Aug-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT00006518	"Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer"	28-Jul-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT00092222	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	19-Aug-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT01419561	History of the KSHV Inflammatory Cytokine Syndrome (KICS)	29-Jul-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT00983424	Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer	16-Sep-13	Completed	3U54CA224065-01S1
clinical_trial	NCT02188264	Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer	2-Apr-21	"Active, not recruiting"	3U54CA224065-01S1
clinical_trial	NCT00003950	"Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer"	7-Mar-14	Completed	3U54CA224065-01S1
clinical_trial	NCT01391143	Safety Study of MGA271 in Refractory Cancer	10-Jan-20	Completed	1U54CA224079-01
clinical_trial	NCT04129320	Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck	14-Oct-20	Withdrawn	1U54CA224079-01
clinical_trial	NCT01942837	Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling	12-Jan-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT01924689	Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies	9-Sep-19	Completed	1UG3CA244687-01
clinical_trial	NCT02807805	"Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer"	19-Mar-21	Recruiting	1U54CA233306-01
clinical_trial	NCT04131413	HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia	6-Jul-21	Recruiting	1U01CA233056-01
clinical_trial	NCT04131413	HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia	6-Jul-21	Recruiting	1U01CA233097-01
clinical_trial	NCT01440088	A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma	2-Jun-16	Completed	3R01CA187532-03S1
clinical_trial	NCT01746979	Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO)	2-Dec-17	Completed	3R01CA187532-03S1
clinical_trial	NCT02267603	Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer	22-Mar-21	"Active, not recruiting"	2UM1CA154967-07
clinical_trial	NCT03747484	Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer	8-Jul-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT02014909	A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors	24-Jul-17	Completed	1U01DE028227-01
clinical_trial	NCT03254927	A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma	28-Apr-21	Completed	1U01DE028227-01
clinical_trial	NCT03338972	Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma	10-Jun-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT03684889	CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma	10-Feb-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT01865617	"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia"	20-Jul-21	Completed	1U01CA247548-01
clinical_trial	NCT03103971	huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia	8-Jul-21	Recruiting	1U01CA247548-01
clinical_trial	NCT02706405	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	16-Jul-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT02631044	Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)	21-Jun-21	Recruiting	1U01CA247548-01
clinical_trial	NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	13-Jul-21	Recruiting	1U01CA247548-01
clinical_trial	NCT03105336	A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)	5-Aug-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT02614066	A Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) (ZUMA-3)	28-Jun-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT03331198	Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)	7-May-21	Recruiting	1U01CA247548-01
clinical_trial	NCT03575351	"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)"	10-Jun-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT02504372	Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (PEARLS)	17-Jul-20	"Active, not recruiting"	1U01CA233102-01
clinical_trial	NCT02998528	A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)	26-Aug-20	"Active, not recruiting"	1U01CA233102-01
clinical_trial	NCT04025879	"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer"	26-Jul-21	Recruiting	1U01CA233102-01
clinical_trial	NCT04214262	Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer	19-Aug-21	Recruiting	1U01CA233102-01
clinical_trial	NCT02884102	MMRF Molecular Profiling Protocol	19-Mar-19	Recruiting	1U2CCA233303-01
clinical_trial	NCT01239134	Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)	14-Aug-19	Completed	1U01CA224348-01
clinical_trial	NCT01239134	Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)	14-Aug-19	Completed	1U2CCA233262-01
clinical_trial	NCT01239134	Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)	14-Aug-19	Completed	3P30CA006516-55S9
clinical_trial	NCT04021043	"BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers"	14-Jan-21	Recruiting	1U01CA224348-01
clinical_trial	NCT04021043	"BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers"	14-Jan-21	Recruiting	1U2CCA233262-01
clinical_trial	NCT04021043	"BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers"	14-Jan-21	Recruiting	3P30CA006516-55S9
clinical_trial	NCT02740270	Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas	21-Feb-21	Completed	1U01CA224348-01
clinical_trial	NCT02740270	Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas	21-Feb-21	Completed	1U2CCA233262-01
clinical_trial	NCT02740270	Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas	21-Feb-21	Completed	3P30CA006516-55S9
clinical_trial	NCT02628574	"Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab"	26-Oct-20	Completed	1U01CA224348-01
clinical_trial	NCT02628574	"Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab"	26-Oct-20	Completed	1U2CCA233262-01
clinical_trial	NCT02628574	"Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab"	26-Oct-20	Completed	3P30CA006516-55S9
clinical_trial	NCT02598960	"An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread."	21-Dec-20	Completed	1U01CA224348-01
clinical_trial	NCT02598960	"An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread."	21-Dec-20	Completed	1U2CCA233262-01
clinical_trial	NCT02598960	"An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread."	21-Dec-20	Completed	3P30CA006516-55S9
clinical_trial	NCT04225039	"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma"	5-Feb-21	Recruiting	1U01CA224348-01
clinical_trial	NCT04225039	"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma"	5-Feb-21	Recruiting	1U2CCA233262-01
clinical_trial	NCT04225039	"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma"	5-Feb-21	Recruiting	3P30CA006516-55S9
clinical_trial	NCT02617589	"An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)"	3-Feb-21	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT02617589	"An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)"	3-Feb-21	"Active, not recruiting"	1U2CCA233262-01
clinical_trial	NCT02617589	"An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)"	3-Feb-21	"Active, not recruiting"	3P30CA006516-55S9
clinical_trial	NCT01804465	Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer	18-Aug-21	Completed	1U01CA233100-01
clinical_trial	NCT01804465	Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer	18-Aug-21	Completed	1U01CA244452-01
clinical_trial	NCT01383538	FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma	8-Aug-17	Completed	1U54CA224083-01
clinical_trial	NCT01195415	Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer	7-Aug-17	Completed	1U54CA224083-01
clinical_trial	NCT01064622	Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer	14-Aug-15	Completed	1U54CA224083-01
clinical_trial	NCT01088815				1U54CA224083-01
clinical_trial	NCT01487785	"Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients"	19-Dec-20	Completed	1U54CA224083-01
clinical_trial	NCT02358161	Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (MATRIX)	9-Jan-20	Completed	1U54CA224083-01
clinical_trial	NCT01373164	A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer	16-May-18	Completed	1U54CA224083-01
clinical_trial	NCT02734160	A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer	5-Aug-19	Completed	1U54CA224083-01
clinical_trial	NCT01821729	Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer	25-Sep-20	"Active, not recruiting"	1U54CA224083-01
clinical_trial	NCT03563248	Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer	20-Jan-21	Recruiting	1U54CA224083-01
clinical_trial	NCT03941093	Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Locally Advanced Pancreatic Cancer	1-Jun-21	Recruiting	1U54CA224083-01
clinical_trial	NCT04054362	Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PINBALL)	16-Dec-19	Unknown	1U54CA224083-01
clinical_trial	NCT04524702	Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer	21-Feb-21	Recruiting	1U54CA224083-01
clinical_trial	NCT03883919	Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy	18-May-21	"Active, not recruiting"	1U54CA224083-01
clinical_trial	NCT03331562	A SU2C Catalyst&#174; Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer	8-Oct-20	Completed	1U54CA224083-01
clinical_trial	NCT03307148	Stromal TARgeting for PAncreatic Cancer (STAR_PAC) (STAR_PAC)	22-Jan-20	Completed	1U54CA224083-01
clinical_trial	NCT02715804	A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	14-Jul-20	Terminated	1U54CA224083-01
clinical_trial	NCT01959139	"S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer"	5-Jan-21	"Active, not recruiting"	1U54CA224083-01
clinical_trial	NCT01472198	A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma	10-Mar-15	Completed	1U54CA224083-01
clinical_trial	NCT03348514	"Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors"	1-Sep-20	Recruiting	3P30CA168524-09S3
clinical_trial	NCT04608045	"Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors"	30-Oct-20	Recruiting	3P30CA168524-09S3
clinical_trial	NCT04525131	"Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors"	19-Dec-20	Recruiting	3P30CA168524-09S3
clinical_trial	NCT03985852	"Broadening the Reach, Impact, and Delivery of Genetic Services (BRIDGE)"	28-Jun-21	Enrolling by invitation	1U01CA232826-01
clinical_trial	NCT01836276	Understanding Disparities in Quitting in African American and White Smokers	24-Oct-18	Completed	3P30CA168524-09S3
clinical_trial	NCT04106219	A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma	18-Aug-21	Recruiting	3P30CA082103-21S9
clinical_trial	NCT04106219	A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma	18-Aug-21	Recruiting	3P30CA082103-21S6
clinical_trial	NCT00719797	Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (TRIBE)	11-Mar-15	Completed	3P30CA014089-45S6
clinical_trial	NCT00433927	"5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)"	14-Mar-14	Unknown	3P30CA014089-45S6
clinical_trial	NCT04365257	Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) (PREVENT)	9-Jun-21	Recruiting	1U01CA247576-01
clinical_trial	NCT02333890	"A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer (CUBiC)"	18-Nov-16	Unknown	3P30CA046592-31S8
clinical_trial	NCT02333890	"A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer (CUBiC)"	18-Nov-16	Unknown	3P30CA046592-31S4
clinical_trial	NCT02378532	The Addition of Chloroquine to Chemoradiation for Glioblastoma (CHLOROBRAIN)	23-Jan-20	Completed	3P30CA046592-31S8
clinical_trial	NCT02378532	The Addition of Chloroquine to Chemoradiation for Glioblastoma (CHLOROBRAIN)	23-Jan-20	Completed	3P30CA046592-31S4
clinical_trial	NCT03400865	Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas	16-Oct-18	Unknown	3P30CA046592-31S8
clinical_trial	NCT03400865	Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas	16-Oct-18	Unknown	3P30CA046592-31S4
clinical_trial	NCT02306954	Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer	3-Mar-20	Recruiting	1U54CA232568-01
clinical_trial	NCT03607617	ASCEND: ApproacheS to CHC ImplEmeNtation of SDH Data Collection and Action (ASCEND)	15-Jun-21	"Active, not recruiting"	1P50CA244289-01
clinical_trial	NCT00546156	Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer	18-May-21	Completed	1U01CA224348-01
clinical_trial	NCT01696877	A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer	28-Mar-19	Completed	3P30CA013696-45S1
clinical_trial	NCT04053062	LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer	27-Jul-20	Recruiting	3P30CA013696-45S1
clinical_trial	NCT03873805	PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer	10-Mar-21	Recruiting	3P30CA013696-45S1
clinical_trial	NCT02186821	Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (SIGNATURE)	8-Apr-21	Terminated	3P30CA168524-09S3
clinical_trial	NCT01749969	"SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients"	26-Mar-21	"Active, not recruiting"	3P30CA082103-21S9
clinical_trial	NCT01749969	"SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients"	26-Mar-21	"Active, not recruiting"	3P30CA082103-21S6
clinical_trial	NCT02098863	Sickle Cell Clinical Research and Intervention Program	1-Mar-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT02588443	Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma	16-Apr-19	Completed	1U01CA224145-01
clinical_trial	NCT02193724	Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma	23-Oct-20	Completed	3P30CA021765-41S3
clinical_trial	NCT00549848	Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia	19-Mar-21	"Active, not recruiting"	3P30CA021765-41S3
clinical_trial	NCT02328677	ColoCare Study - Colorectal Cancer Cohort	19-Oct-20	Recruiting	3P30CA042014-31S5
clinical_trial	NCT04131062	Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants	22-Jan-21		1R01CA211723-01A1
clinical_trial	NCT03698162	Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases	5-Apr-21		1R33CA225400-01
clinical_trial	NCT01946789	A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors	17-Apr-19		2UM1CA154967-07
clinical_trial	NCT01961115	Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma	8-Jun-18	Completed	2UM1CA154967-07
clinical_trial	NCT04751383	Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma	12-Feb-21		2UM1CA154967-07
clinical_trial	NCT04500548	"Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study"	18-Aug-21		2UM1CA154967-07
clinical_trial	NCT03513952	"Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma"	11-Aug-21		2UM1CA154967-07
clinical_trial	NCT01727076	"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer"	15-Sep-17		2UM1CA154967-07
clinical_trial	NCT04410302	Patient-Derived Xenografts to Reduce Cancer Health Disparities	13-Jul-21		1U54CA233306-01
clinical_trial	NCT04406714	"Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE)"	12-May-21		1UG3CA233251-01
clinical_trial	NCT04427527	Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia	3-May-21		1UG3CA233282-01
clinical_trial	NCT03892967	"Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) Pragmatic Clinical Trial"	13-Aug-21		1UM1CA233033-01
clinical_trial	NCT03988543	"Bilingual Electronic Symptom Management Program Across Multi-site, Comprehensive Cancer Center"	3-Mar-21		1UM1CA233035-01
clinical_trial	NCT03850912	Symptom Management Implementation of Patient Reported Outcomes in Oncology	16-Sep-20		1UM1CA233080-01
clinical_trial	NCT04199026	Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma	6-Mar-20		3R01CA180279-05S1
clinical_trial	NCT03538938	Improving Quitline Support Study	17-May-21		5R01CA218156-02
clinical_trial	NCT04314284	Patient-Centered Intervention to Reduce Cancer Patients&apos; Financial Toxicity	14-Jan-21		1P50CA244431-01
clinical_trial	NCT04585919	Paired Promotion of Colorectal Cancer and Social Determinants of Health Screening	1-Apr-21		1P50CA244433-01
clinical_trial	NCT04337203	Shared Healthcare Actions and Reflections Electronic Systems in Survivorship	18-Jun-21		1P50CA244693-01
clinical_trial	NCT04746794	Early Detection of GEnetic Risk (EDGE)	10-Feb-21		1U01CA232795-01A1
clinical_trial	NCT04323774	Intervention For AYAS With Cancer Risk Syndromes	13-Apr-21		1U01CA243688-01
clinical_trial	NCT04939597	A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor	25-Jun-21		1U01CA246568-01
clinical_trial	NCT04789720	Using Information Technology to Improve Outcomes for Children Living With Cancer	18-Jun-21		1U01CA246612-01
clinical_trial	NCT04089358	"Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study"	23-Jul-21		1U01CA246665-01
clinical_trial	NCT04941300	ColoRectal Cancer Screening for Southern California Community Health Centers	19-Jul-21		1UG3CA233314-01A1
clinical_trial	NCT04890054	"Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC"	15-Jul-21		1UG3CA244298-01
clinical_trial	NCT04745754	The Engaging Primary Care in Cancer Survivorship (EPICS) Study	4-Aug-21		1R01CA249419-01
clinical_trial	NCT05006482	Geriatric Evaluation and Management With Survivorship Health Education (GEMS) for Older Survivors of Cancer	16-Aug-21	Not yet recruiting	1R01CA249467-01
clinical_trial	NCT04428905	Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer	16-Feb-21		1R01CA249501-01
clinical_trial	NCT04494945	Identifying and Caring for Individuals With Inherited Cancer Syndrome	2-Jun-21		1U01CA232819-01A1
clinical_trial	NCT04597359	To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring	14-Jul-21		3UG1CA189828-07S1
clinical_trial	NCT04467021	"Cancer and Blood Pressure Management, CARISMA Study"	5-Mar-21		3UG1CA189828-07S1
clinical_trial	NCT04438382	Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis	22-Jul-21		3UG1CA189828-07S1
clinical_trial	NCT04239573	Comparing Two Methods to Follow Patients With Pancreatic Cysts	6-Aug-21		3UG1CA189828-07S1
clinical_trial	NCT04001829	Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer	12-Jul-21		3UG1CA189828-07S1
clinical_trial	NCT03804255	Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting	3-Nov-20		3UG1CA189828-07S1
clinical_trial	NCT02352883	MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ	26-Oct-20		3UG1CA189828-07S1
clinical_trial	NCT03253848	Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia	9-Mar-21		3UG1CA189828-07S1
clinical_trial	NCT02933489	Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts	5-Feb-21	"Active, not recruiting"	3UG1CA189828-07S1
clinical_trial	NCT03904862	Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery	22-Jun-20		2UM1CA081457-21
clinical_trial	NCT03033992	Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma	15-Feb-21		2UM1CA081457-21
clinical_trial	NCT01836549	Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors	20-Jul-18	Terminated	2UM1CA081457-21
clinical_trial	NCT00503724	Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors	6-Mar-12		2UM1CA081457-21
clinical_trial	NCT00357253	"Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma"	10-Jan-13		2UM1CA081457-21
clinical_trial	NCT00112619	"Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors"	30-Jun-11		2UM1CA081457-21
clinical_trial	NCT01158300	PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors	4-May-15		2UM1CA081457-21
clinical_trial	NCT00572182	MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer	6-Mar-12		2UM1CA081457-21
clinical_trial	NCT00021229	Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma	31-Jul-14	Terminated	2UM1CA081457-21
clinical_trial	NCT04870944	"CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma"	4-May-21		5UM1CA228823-03
clinical_trial	NCT04851119	"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors"	20-Apr-21		5UM1CA228823-03
clinical_trial	NCT04158739	Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia	23-Jul-21		5UM1CA228823-03
clinical_trial	NCT01031953	Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy	9-May-17	Terminated	3P30CA069533-22S5
clinical_trial	NCT00900055	"Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma"	24-Jul-20		3P30CA069533-22S5
clinical_trial	NCT01913015	Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer	28-Apr-17		3P30CA069533-22S5
clinical_trial	NCT01649505	Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction	15-Mar-13	Terminated	3P30CA069533-22S5
clinical_trial	NCT01005914	Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	4-Mar-15	Terminated	3P30CA069533-22S5
clinical_trial	NCT00900302	OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer	10-Feb-16		3P30CA069533-22S5
clinical_trial	NCT00899795	"Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers"	4-Dec-17		3P30CA069533-22S5
clinical_trial	NCT03677531	Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy	4-May-20		3P30CA069533-22S5
clinical_trial	NCT03479268	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	7-Jul-21		3P30CA069533-22S5
clinical_trial	NCT03261180	Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer	25-Feb-20		3P30CA069533-22S5
clinical_trial	NCT00567229	Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma	20-Nov-15	Terminated	3P30CA008748-54S3
clinical_trial	NCT00550628	Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer	23-Dec-15		3P30CA008748-54S3
clinical_trial	NCT00541034	"Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia"	11-Aug-17	Completed	3P30CA008748-54S3
clinical_trial	NCT00519974	Factors Affecting Decisions About Breast Reconstruction After Mastectomy in Black and Latina Women	1-Oct-15		3P30CA008748-54S3
clinical_trial	NCT00514254	Risk Factors for Endometrial Cancer in Black Women	10-Aug-21		3P30CA008748-54S3
clinical_trial	NCT00483678	Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners	6-Mar-18		3P30CA008748-54S3
clinical_trial	NCT00471679	Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma	5-Mar-13		3P30CA008748-54S3
clinical_trial	NCT00471601	Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions	5-Oct-20		3P30CA008748-54S3
clinical_trial	NCT00470574	Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer	18-Nov-20	Completed	3P30CA008748-54S3
clinical_trial	NCT00462982	Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma	30-Dec-15	Completed	3P30CA008748-54S3
clinical_trial	NCT01418495	Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma	1-Oct-19		3P30CA016520-44S5
clinical_trial	NCT01418495	Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma	1-Oct-19		3P30CA016520-44S6
clinical_trial	NCT00679094	Bowman-Birk Inhibitor Concentrate in Healthy Men	29-Dec-16		3P30CA016520-44S5
clinical_trial	NCT00679094	Bowman-Birk Inhibitor Concentrate in Healthy Men	29-Dec-16		3P30CA016520-44S6
clinical_trial	NCT01873833	"Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer"	14-May-19		3P30CA014089-45S6
clinical_trial	NCT04981834	Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer	29-Jul-21	Not yet recruiting	3P30CA014089-45S6
clinical_trial	NCT04941430	7T MRI Scan for the Early Detection of Melanoma Brain Metastases	28-Jun-21		3P30CA014089-45S6
clinical_trial	NCT04927559	Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy	16-Jun-21		3P30CA014089-45S6
clinical_trial	NCT04832763	Medical and Psychosocial Issues in Adolescents and Young Adults With Colorectal Cancer	6-Apr-21		3P30CA014089-45S6
clinical_trial	NCT04830735	Dasatinib for the Treatment of Moderate and Severe COVID-19	10-Jun-21		3P30CA014089-45S6
clinical_trial	NCT04752267	18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases	17-Mar-21		3P30CA014089-45S6
clinical_trial	NCT04387084	Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy	5-Apr-21		3P30CA014089-45S6
clinical_trial	NCT04387071	CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma	5-Apr-21		3P30CA014089-45S6
clinical_trial	NCT04373044	"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19"	26-May-21		3P30CA014089-45S6
clinical_trial	NCT02189486	Prostate Cancer Upgrading Reference Set	30-Jun-21		3P30CA054174-25S2
clinical_trial	NCT02189486	Prostate Cancer Upgrading Reference Set	30-Jun-21		3P30CA054174-25S1
clinical_trial	NCT00055822	Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer	4-Jul-12		3P30CA054174-25S2
clinical_trial	NCT00055822	Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer	4-Jul-12		3P30CA054174-25S1
clinical_trial	NCT00003709	Chemotherapy in Treating Patients With Advanced Solid Tumors	9-Aug-12		3P30CA054174-25S2
clinical_trial	NCT00003709	Chemotherapy in Treating Patients With Advanced Solid Tumors	9-Aug-12		3P30CA054174-25S1
clinical_trial	NCT00003760	Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer	9-Aug-12		3P30CA054174-25S2
clinical_trial	NCT00003760	Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer	9-Aug-12		3P30CA054174-25S1
clinical_trial	NCT00003708	Chemotherapy in Treating Patients With Advanced Solid Tumors	9-Aug-12		3P30CA054174-25S2
clinical_trial	NCT00003708	Chemotherapy in Treating Patients With Advanced Solid Tumors	9-Aug-12		3P30CA054174-25S1
clinical_trial	NCT00003710	Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors	9-Aug-12		3P30CA054174-25S2
clinical_trial	NCT00003710	Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors	9-Aug-12		3P30CA054174-25S1
clinical_trial	NCT00003706	LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function	28-Jun-12		3P30CA054174-25S2
clinical_trial	NCT00003706	LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function	28-Jun-12		3P30CA054174-25S1
clinical_trial	NCT00003712	CCI-779 in Treating Patients With Advanced Solid Tumors	9-Aug-12		3P30CA054174-25S2
clinical_trial	NCT00003712	CCI-779 in Treating Patients With Advanced Solid Tumors	9-Aug-12		3P30CA054174-25S1
clinical_trial	NCT00003707	Combination Chemotherapy in Treating Patients With Advanced Cancer	28-Jun-12		3P30CA054174-25S2
clinical_trial	NCT00003707	Combination Chemotherapy in Treating Patients With Advanced Cancer	28-Jun-12		3P30CA054174-25S1
clinical_trial	NCT00003721	Chemotherapy in Treating Patients With Advanced Solid Tumors	29-Jun-12		3P30CA054174-25S2
clinical_trial	NCT00003721	Chemotherapy in Treating Patients With Advanced Solid Tumors	29-Jun-12		3P30CA054174-25S1
clinical_trial	NCT00064272	UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer	21-Oct-16		3P30CA046592-31S8
clinical_trial	NCT00064272	UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer	21-Oct-16		3P30CA046592-31S4
clinical_trial	NCT00098969	UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants	17-Dec-12		3P30CA046592-31S8
clinical_trial	NCT00098969	UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants	17-Dec-12		3P30CA046592-31S4
clinical_trial	NCT00967824	Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer	24-Mar-11		3P30CA046592-31S8
clinical_trial	NCT00967824	Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer	24-Mar-11		3P30CA046592-31S4
clinical_trial	NCT00955188	Computer-Based Tailored or Standard Information for Colorectal Cancer Screening	21-Dec-12		3P30CA046592-31S8
clinical_trial	NCT00955188	Computer-Based Tailored or Standard Information for Colorectal Cancer Screening	21-Dec-12		3P30CA046592-31S4
clinical_trial	NCT00900094	UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer	7-Feb-12		3P30CA046592-31S8
clinical_trial	NCT00900094	UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer	7-Feb-12		3P30CA046592-31S4
clinical_trial	NCT00003076	Eflornithine to Prevent Cancer in Patients With Barrett&apos;s Esophagus	19-Dec-12		3P30CA046592-31S8
clinical_trial	NCT00003076	Eflornithine to Prevent Cancer in Patients With Barrett&apos;s Esophagus	19-Dec-12		3P30CA046592-31S4
clinical_trial	NCT00005598	Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome	21-Dec-12		3P30CA046592-31S8
clinical_trial	NCT00005598	Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome	21-Dec-12		3P30CA046592-31S4
clinical_trial	NCT00003598	UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia	22-Sep-10		3P30CA046592-31S8
clinical_trial	NCT00003598	UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia	22-Sep-10		3P30CA046592-31S4
clinical_trial	NCT00027495	Curcumin for the Prevention of Colon Cancer	21-Dec-12		3P30CA046592-31S8
clinical_trial	NCT00027495	Curcumin for the Prevention of Colon Cancer	21-Dec-12		3P30CA046592-31S4
clinical_trial	NCT02007200	Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery	24-Oct-16	Completed	3P30CA046592-31S8
clinical_trial	NCT02007200	Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery	24-Oct-16	Completed	3P30CA046592-31S4
clinical_trial	NCT01700959	Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort	28-Jun-18	Completed	3P30CA021765-41S3
clinical_trial	NCT00004006	"Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma"	4-Oct-11		3P30CA021765-41S3
clinical_trial	NCT00004005	"Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin"	26-Apr-17		3P30CA021765-41S3
clinical_trial	NCT00137111	Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia	11-Sep-20	Completed	3P30CA021765-41S3
clinical_trial	NCT00576472	Learning Impairments Among Survivors of Childhood Cancer	30-May-17	Completed	3P30CA021765-41S3
clinical_trial	NCT00002794	Carboplatin Plus Vincristine in Treating Children With Retinoblastoma	4-Oct-11		3P30CA021765-41S3
clinical_trial	NCT00004068	Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor	4-Oct-11		3P30CA021765-41S3
clinical_trial	NCT00002748	Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma	4-Oct-11		3P30CA021765-41S3
clinical_trial	NCT00101205	"Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma"	24-Feb-14		3P30CA021765-41S3
clinical_trial	NCT04662645	Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers	10-Dec-20		3P30CA016058-44S3
clinical_trial	NCT04602026	"Re-Defining Frailty and Improving Outcomes Through Prehabilitation in Patients With Pancreatic, Liver, or Gastric Cancer, The RIOT Trial"	27-Oct-20		3P30CA016058-44S3
clinical_trial	NCT04439006	Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization	19-Aug-20		3P30CA016058-44S3
clinical_trial	NCT04329962	Metabolism and Absorption of Anthocyanins From Extract and Whole Blueberry Powder Confections in Healthy Adults	1-Apr-20		3P30CA016058-44S3
clinical_trial	NCT04269837	Sexual Health Counseling Intervention During Radiation Therapy in Improving Quality of Life for Women With Gynecologic Cancer	8-Dec-20		3P30CA016058-44S3
clinical_trial	NCT04229381	Resiliency Among Older Adults Receiving Lung Cancer Treatment	18-Jan-20		3P30CA016058-44S3
clinical_trial	NCT04220684	Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	4-Jun-20		3P30CA016058-44S3
clinical_trial	NCT04205071	Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer	19-Jan-21		3P30CA016058-44S3
clinical_trial	NCT04164069	Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab	8-Jul-21		3P30CA016058-44S3
clinical_trial	NCT04120454	Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer	9-Oct-20		3P30CA016058-44S3
clinical_trial	NCT04162873	Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer	17-Aug-20		3P30CA042014-31S5
clinical_trial	NCT04106856	Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)	16-Jul-21		3P30CA042014-31S5
clinical_trial	NCT03987217	Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients	13-Jan-21		3P30CA042014-31S5
clinical_trial	NCT03972943	CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia	22-Apr-21		3P30CA042014-31S5
clinical_trial	NCT03900767	Strategies to Connect Patients at Federally Qualified Health Clinics With Evidence Based Tobacco Cessation Treatment	3-Apr-19		3P30CA042014-31S5
clinical_trial	NCT00335491	Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors	30-Sep-11		3P30CA042014-31S5
clinical_trial	NCT00026468	Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis	24-Jul-13		3P30CA042014-31S5
clinical_trial	NCT02337517	Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease	19-Jul-21	Terminated	3P30CA042014-31S5
clinical_trial	NCT02159755	Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma	21-May-21		3P30CA013696-45S1
clinical_trial	NCT00233935	Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett&apos;s Esophagus	11-Sep-14		3P30CA013696-45S1
clinical_trial	NCT04109924	"TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study"	23-Jul-21		3P30CA016056-43S5
clinical_trial	NCT00957424	Acceptability of Less Harmful Alternatives to Cigarettes	7-Feb-17	Completed	3P30CA016056-43S5
clinical_trial	NCT00849186	Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer	6-Feb-15	Completed	3P30CA016056-43S5
clinical_trial	NCT00736164	Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer	6-Feb-12		3P30CA016056-43S5
clinical_trial	NCT01892930	Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery	10-Feb-17		3P30CA016056-43S5
clinical_trial	NCT00690924	Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer	4-Jun-18	Completed	3P30CA016056-43S5
clinical_trial	NCT01769885	Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer	11-Apr-17		3P30CA016056-43S5
clinical_trial	NCT00560495	"Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer"	10-Feb-12		3P30CA016056-43S5
clinical_trial	NCT01555268	Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia	15-Feb-17		3P30CA016056-43S5
clinical_trial	NCT00217516	Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer	9-Feb-12		3P30CA016056-43S5
clinical_trial	NCT00095927	Randomized Amifostine For SCCHN	4-Jan-17		3P30CA006516-55S9
clinical_trial	NCT00095901	Capecitabine For Nasopharyngeal Cancer	29-Mar-18		3P30CA006516-55S9
clinical_trial	NCT00084838	Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT	24-Dec-15	Completed	3P30CA006516-55S9
clinical_trial	NCT00069940	Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor	28-Dec-10		3P30CA006516-55S9
clinical_trial	NCT03029325	Molecular and Genetic Analysis of Lung Cancer	4-Mar-21		3P30CA006516-55S9
clinical_trial	NCT00429910	Natural History Study of Patients With Chronic Myelogenous Leukemia	2-Jan-17		3P30CA006516-55S9
clinical_trial	NCT00357500	"Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer"	1-Oct-14	Completed	3P30CA006516-55S9
clinical_trial	NCT00101075	Title XELOX FOR SALIVARY GLAND CANCERS	27-Feb-17		3P30CA006516-55S9
clinical_trial	NCT00098865	Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma	7-Oct-14	Completed	3P30CA006516-55S9
clinical_trial	NCT00095875	Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)	19-Nov-13	Completed	3P30CA006516-55S9
